Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Company Deals Digital

SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model

Fineline Cube Apr 24, 2026
Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC

Fineline Cube Apr 27, 2026
Company Drug

China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis

Fineline Cube Apr 24, 2026
Company Drug

CStone Pharmaceuticals Receives NMPA Approval for Local Production of Gavreto in China

Fineline Cube Jul 10, 2025

China-based CStone Pharmaceuticals (HKG: 2616) has announced that it has received approval from the National...

Company Deals

Biocytogen and BeOne Medicines Deepen Partnership with Global Antibody Licensing Agreement

Fineline Cube Jul 10, 2025

China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has announced a global antibody molecule licensing...

Company Drug

Eli Lilly’s Kisunla (Donanemab) Receives FDA Label Update with New Dosing Schedule for Alzheimer’s Treatment

Fineline Cube Jul 10, 2025

US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has announced that the US Food...

Company Drug

Jiangsu Chia Tai Tianqing’s Culmerciclib Receives NMPA Review for Expanded Breast Cancer Indication

Fineline Cube Jul 10, 2025

Subsidiary of China based Sino Biopharmaceutical Ltd (HKG: 1177) Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...

Company Deals

Sironax Partners with Novartis on Brain Delivery Module Platform for CNS Drugs

Fineline Cube Jul 10, 2025

China-based biotech innovator Sironax has entered into a strategic agreement with Swiss pharmaceutical giant Novartis...

Company Deals

Novo Nordisk Invests $111 Million in Tianjin Quality Control Lab Expansion

Fineline Cube Jul 10, 2025

Denmark-based pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) has signed a Memorandum of Understanding (MOU)...

Company Drug

Simcere and Connect Biopharma’s Rademikibart NDA Accepted by China’s NMPA for Atopic Dermatitis

Fineline Cube Jul 10, 2025

The New Drug Application (NDA) for rademikibart, an anti-inflammatory monoclonal antibody (mAb) co-developed by China’s...

Company Deals

Anke Bio Secures Exclusive Rights to Bao Pharma’s Long-Acting FSH-CTP for China Market

Fineline Cube Jul 10, 2025

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced an exclusive distribution agreement with...

Company Deals Medical Device

ShuWen Biotech Completes RMB100 Million Series C1 Round to Advance Women’s Health Diagnostics

Fineline Cube Jul 10, 2025

Zhejiang-based ShuWen Biotech Co., Ltd announced the successful completion of an RMB100 million (USD 14...

Company Drug

IASO Biotherapeutics Receives Orphan Drug Designation in South Korea for Fucaso in Multiple Myeloma

Fineline Cube Jul 10, 2025

China-based IASO Biotherapeutics announced that its BCMA-targeted chimeric antigen receptor (CAR) T cell therapy, Fucaso...

Company Deals

MSD to Acquire Verona Pharma for $10 Billion, Expanding Respiratory Portfolio

Fineline Cube Jul 10, 2025

In a landmark deal poised to reshape the respiratory disease treatment landscap US pharmaceutical giant...

Company Drug

Guangdong Taienkang Submits Marketing Application for Generic Vuity to China’s NMPA

Fineline Cube Jul 9, 2025

China-based Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced the submission of a marketing approval...

Company

Pascal Qian Appointed General Manager of BMS China Unit

Fineline Cube Jul 9, 2025

Pascal Qian this week officially assumed the role of General Manager of Bristol-Myers Squibb’s (BMS;...

Company Deals

Adagene Collaborates with ConjugateBio to Develop Bispecific Antibody Drug Conjugates

Fineline Cube Jul 9, 2025

China-based Adagene Inc. (NASDAQ: ADAG) announced a strategic collaboration with US-headquartered biotech ConjugateBio Inc. to...

Company Deals

Zhaoke Ophthalmology Partners with Somerset Therapeutics to Accelerate US Expansion

Fineline Cube Jul 9, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced last month a strategic partnership with US generic...

Company Deals

LakeShore Biopharma Secures $15 Million in Private Placement to Fuel Growth

Fineline Cube Jul 9, 2025

China-based biopharmaceutical company LakeShore Biopharma Co., Ltd (NASDAQ: LSB) has announced the successful execution of...

Company Drug

Innovent’s Dabote Becomes First China-Originated KRAS G12C Inhibitor Approved in Macau

Fineline Cube Jul 9, 2025

China-based biopharma leader Innovent Biologics Inc. (HKG: 1801) has announced a significant regulatory milestone with...

Company Deals

NK CellTech Secures $14 Million in Series A+++ Financing to Advance NK Cell Therapies

Fineline Cube Jul 9, 2025

China-based biotech innovator NK CellTech has successfully closed its Series A+++ financing round, raising RMB...

Company Drug

Hengrui Pharmaceuticals Receives NMPA Clearance for SHR-2173 in Primary Membranous Nephropathy

Fineline Cube Jul 9, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clearance from...

Company Drug

J&J Submits sNDA to FDA for Caplyta to Prevent Schizophrenia Relapse

Fineline Cube Jul 9, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced the submission of a supplemental New...

Posts pagination

1 … 120 121 122 … 656

Recent updates

  • NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting
  • Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics
  • AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC
  • Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline
  • Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Others

Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics

Company Drug

AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC

Company R&D

Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.